Low-Dose Aspirin Does Not Reduce Skin Cancer Incidence
The current evidence does not support using low-dose aspirin (81 mg daily) specifically for skin cancer prevention. While some observational data suggest potential modest benefits for non-melanoma skin cancers, the evidence is inconsistent, and no major clinical guidelines recommend aspirin for this indication.
Evidence Summary
Mixed Research Findings
The research evidence on aspirin and skin cancer shows conflicting results:
Potential modest benefit for non-melanoma skin cancers:
- A 2015 meta-analysis found that aspirin intake was associated with a small reduction in overall skin cancer risk (OR 0.94,95% CI 0.90-0.99), with the effect primarily seen in non-melanoma skin cancers (OR 0.97,95% CI 0.95-0.99) 1
- Another 2015 systematic review showed nonaspirin NSAIDs reduced squamous cell carcinoma risk (RR 0.85,95% CI 0.78-0.94), with borderline significance for aspirin alone (RR 0.88,95% CI 0.75-1.03) 2
No benefit or potential harm for melanoma:
- The large Nurses' Health Study found no protective effect of aspirin against melanoma, squamous cell carcinoma, or basal cell carcinoma. Paradoxically, current aspirin users had an increased melanoma risk (RR 1.32,95% CI 1.03-1.70), though this likely reflects confounding rather than causation 3
- A 2024 review concluded that evidence for melanoma prevention remains "complex with conflicting findings" and lacks consistency 4
Long-term use data:
- A 2024 Danish cohort study of nearly 2 million people found that while long-term low-dose aspirin reduced risk for several cancers (colon, liver, pancreas), it showed substantially elevated risks for lung and bladder cancer and did not reduce overall cancer risk (HR 1.04,95% CI 1.03-1.06) 5
Absence of Guideline Support
Critically, none of the provided clinical guidelines address aspirin for skin cancer prevention. The guidelines focus exclusively on:
- Cardiovascular disease prevention 6
- Colorectal cancer prevention (as a secondary consideration alongside cardiovascular benefits) 7
- Diabetes management 8
- Pregnancy-related preeclampsia prevention 9
The 2016 USPSTF commentary explicitly states: "the present USPSTF decision does not endorse aspirin use for the sole purpose of cancer prevention" beyond colorectal cancer 7. The commentary notes that while "several compelling studies have suggested such benefits with aspirin use associated with lower risk of esophageal, breast, prostate, and lung cancer," these findings require validation before population-based recommendations can be made 7.
Clinical Bottom Line
Do not prescribe low-dose aspirin for skin cancer prevention. The evidence is:
- Inconsistent across studies
- Shows only modest effects at best for non-melanoma skin cancers
- Demonstrates no clear benefit for melanoma
- Lacks support from any major clinical guideline
- Carries well-established bleeding risks that outweigh unproven skin cancer benefits
When Aspirin IS Appropriate
If your patient has established cardiovascular disease or meets criteria for primary cardiovascular prevention (10-year CVD risk >10% in ages 50-69), then prescribe aspirin 75-100 mg daily for cardiovascular indications 6, 8. Any potential skin cancer benefit would be incidental, not the primary justification.
Common Pitfalls to Avoid
- Do not extrapolate colorectal cancer data to skin cancer - the mechanisms and evidence base differ substantially
- Do not ignore bleeding risks - gastrointestinal bleeding, hemorrhagic stroke, and other bleeding complications occur with aspirin use, particularly in older adults 8, 10
- Do not use aspirin in patients <50 years for cancer prevention - insufficient benefit-to-risk ratio 8
- Do not use aspirin in patients >70 years for primary prevention - greater risk than benefit 8
The appropriate strategy for skin cancer prevention remains sun protection, regular skin examinations, and surveillance in high-risk patients—not aspirin chemoprevention.